Computational approach to target USP28 for regulating Myc

Myc is a crucial player in cellular proliferation and a known regulator of cancer pathobiology. Modulation of Myc expression targeting the Myc Protein-Protein Interactors (PPIs) like Myc-Max has till now been the most explored approach. However, this approach threatens the normal cells where Myc expression is required for proliferation. This demands the need for a new strategy to indirectly modulate Myc expression. Indirect modulation can be achieved by regulating Myc turnover. FBXW7 mediates the ubiquitination and subsequent degradation of Myc which is reversed by USP28. In this study, the interaction of USP28 with FBXW7 as well as with its substrate, Ubiquitin (Ub) were used as targets. Computation based high-throughput screening of bioactive small chemicals using molecular docking method was implemented to predict USP28 inhibitors. For the two regions, docking study with AutoDock Vina gave top 10 best scoring drugs which were identified and tabulated. The two regions defined in the study as FBXW7 binding and Ub binding also encompass the areas in which USP28 differed from USP25, a homologue with a different role. Out of these the best scoring drugs were explored for their role in cancer, if any. This study was performed keeping in mind re-purposing of these known drugs for possible alternative anti-Myc cancer therapy.

[1]  J. Ingram,et al.  Metoclopramide or domperidone for increasing maternal breast milk output: a randomised controlled trial , 2011, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[2]  Zhiping Weng,et al.  ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers , 2014, Bioinform..

[3]  J. Boros,et al.  Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily. , 2017, ACS chemical biology.

[4]  C. Feng,et al.  Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model , 2013, Cancer Cell International.

[5]  H. Shu,et al.  Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6 , 2015, Proceedings of the National Academy of Sciences.

[6]  J. Rain,et al.  Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells , 2009, Molecular Cancer Therapeutics.

[7]  M. Bayés,et al.  Characterization of alternatively spliced products and tissue-specific isoforms of USP28 and USP25 , 2001, Genome Biology.

[8]  Dima Kozakov,et al.  ClusPro-DC: Dimer Classification by the Cluspro Server for Protein-Protein Docking. , 2017, Journal of molecular biology.

[9]  Colin J. Daniel,et al.  Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer , 2014, Proceedings of the National Academy of Sciences.

[10]  Rodrigo Lopez,et al.  Programmatic access to bioinformatics tools from EMBL-EBI update: 2017 , 2017, Nucleic Acids Res..

[11]  Tao Jiang,et al.  Accelerated similarity searching and clustering of large compound sets by geometric embedding and locality sensitive hashing , 2010, Bioinform..

[12]  T. Mak,et al.  A Role for the Deubiquitinating Enzyme USP28 in Control of the DNA-Damage Response , 2006, Cell.

[13]  W. Park,et al.  Intravesical instillation of c-MYC inhibitor KSI-3716 suppresses orthotopic bladder tumor growth. , 2014, The Journal of urology.

[14]  David E. Muench,et al.  c-Myc and Cancer Metabolism , 2012, Clinical Cancer Research.

[15]  L. Iakoucheva,et al.  Intrinsic disorder in cell-signaling and cancer-associated proteins. , 2002, Journal of molecular biology.

[16]  F. Radvanyi,et al.  MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors , 2006, Oncogene.

[17]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[18]  D. Cunningham,et al.  Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens. , 1987, British medical journal.

[19]  M. Eilers,et al.  Usp28 counteracts Fbw7 in intestinal homeostasis and cancer. , 2015, Cancer research.

[20]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[21]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[22]  J. Fox,et al.  Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-Myc in mice , 2014, Proceedings of the National Academy of Sciences.

[23]  Evan Bolton,et al.  PubChem 2019 update: improved access to chemical data , 2018, Nucleic Acids Res..

[24]  J. Adams,et al.  Development of the Proteasome Inhibitor Velcade™ (Bortezomib) , 2004, Cancer investigation.

[25]  J. Whitfield,et al.  Strategies to Inhibit Myc and Their Clinical Applicability , 2017, Front. Cell Dev. Biol..

[26]  C. Kisker,et al.  Differential Oligomerization of the Deubiquitinases USP25 and USP28 Regulates Their Activities. , 2019, Molecular cell.

[27]  L. Penn,et al.  MYC Deregulation in Primary Human Cancers , 2017, Genes.

[28]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[29]  S. Elledge,et al.  The ubiquitin-specific protease USP28 is required for MYC stability , 2007, Nature Cell Biology.

[30]  E. Prochownik,et al.  Pharmacophore identification of c-Myc inhibitor 10074-G5. , 2013, Bioorganic & medicinal chemistry letters.

[31]  R. Sears.  The Life Cycle of C-Myc: From Synthesis to Degradation , 2004, Cell cycle.

[32]  Bo Yu,et al.  CDD/SPARCLE: functional classification of proteins via subfamily domain architectures , 2016, Nucleic Acids Res..

[33]  Wei Zheng,et al.  Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant Acinetobacter baumannii , 2019, Front. Cell. Infect. Microbiol..

[34]  M. Groudine,et al.  Control of c-myc regulation in normal and neoplastic cells. , 1991, Advances in cancer research.

[35]  Robert B. Russell,et al.  PepSite: prediction of peptide-binding sites from protein surfaces , 2012, Nucleic Acids Res..

[36]  René Bernards,et al.  A Genomic and Functional Inventory of Deubiquitinating Enzymes , 2005, Cell.

[37]  M. Hartnett,et al.  Domperidone, a new dopamine antagonist. , 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[38]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[39]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[40]  R. Rodríguez-Barrueco,et al.  MYC is a critical target of FBXW7 , 2014, Oncotarget.

[41]  M. Mezei,et al.  Molecular docking: a powerful approach for structure-based drug discovery. , 2011, Current computer-aided drug design.

[42]  David Komander,et al.  Breaking the chains: structure and function of the deubiquitinases , 2009, Nature Reviews Molecular Cell Biology.

[43]  I. Ahel,et al.  Discovery and Characterization of ZUFSP/ZUP1, a Distinct Deubiquitinase Class Important for Genome Stability , 2018, Molecular cell.

[44]  I. Mérida,et al.  Diacylglycerol kinase α promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src , 2014, Oncotarget.

[45]  L. Hurley,et al.  Demonstration that Drug-targeted Down-regulation of MYC in Non-Hodgkins Lymphoma Is Directly Mediated through the Promoter G-quadruplex* , 2011, The Journal of Biological Chemistry.

[46]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[47]  D S Goodsell,et al.  Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.

[48]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[49]  J Wade Harper,et al.  Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. , 2007, Molecular cell.

[50]  B. Graves,et al.  Distinct USP25 and USP28 Oligomerization States Regulate Deubiquitinating Activity , 2019, Molecular cell.

[51]  A. Ciechanover,et al.  The 26 S Proteasome: From Basic Mechanisms to Drug Targeting* , 2009, The Journal of Biological Chemistry.

[52]  R. Wisdom,et al.  Translation of c-myc mRNA is required for its post-transcriptional regulation during myogenesis. , 1990, The Journal of biological chemistry.